Loading patent…
AssigneePfizer Inc.
InventorsChristine Ellen Bulawa, James Allan Fleming
Estimating the term…
The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis.
A method of treating TTR amyloidosis in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents wherein the additional therapeutic agent is ataluren.
A method of inhibiting TTR fibril formation in a patient, the method comprising administering a therapeutically effective amount of ataluren or a pharmaceutically acceptable salt thereof to a patient.
Dependencies are inferred from the claim text.